Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer.

@article{Loprinzi1994PlacebocontrolledTO,
  title={Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer.},
  author={Charles L Loprinzi and Richard M. Goldberg and John Q. Su and James A. Mailliard and Steven A. Kuross and Andrew W. Maksymiuk and John W. Kugler and James R. Jett and Chirantan Ghosh and Delano M. Pfeifle},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1994},
  volume={12 6},
  pages={1126-9}
}
PURPOSE Hydrazine sulfate, an agent that appears to inhibit gluconeogenesis, has been studied in cancer patients for approximately 20 years. There was a recent resurgence of interest in this drug when subset analysis of a small placebo-controlled, double-blind, clinical trial reported improved survival among non-small-cell lung cancer patients with a good performance status who were randomized to receive this drug along with standard chemotherapy. PATIENTS AND METHODS Patients on this trial… CONTINUE READING
16 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…